SynthesisBMC cancer2025
Associations between psoriasis and risk of 33 cancers: a Mendelian randomization study.
Synthesis in BMC cancer, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Integrative multidimensional analysis of age-associated synthetic lethal genes and development of a prognostic model in breast cancer.Frontiers in immunology · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
backgroundSeveral observational studies have reported epidemiologic associations between psoriasis and risk of some cancers, but systematic evidence is lacking. Our aim was to comprehensively estimate the association between psoriasis and the risk of 33 common cancers using systematical Mendelian randomization based on genetic data.
methodForty-nine independent single-nucleotide polymorphisms (SNPs) significantly associated with psoriasis were extracted as instrumental variables from a large-scale meta-analysis study of genome-wide association study (GWAS) for psoriasis. Outcome GWAS data were obtained from the FinnGen consortium (n = 500,348), UK Biobank (n = 420,531), and other large-scale cancer datasets. The inverse-variance weighted (IVW) was used as the primary method to infer the association between psoriasis and risk of cancer, and finally the results from multiple databases were pooled by meta-analysis.
resultsIn the UK Biobank, genetically predicted psoriasis had a suggestive association with colon (OR = 1.055, 95%CI: 1.001-1.113, P = 0.046) and uterine corpus cancer (OR = 0.922, 95%CI: 0.852-0.997, P = 0.042). In the FinnGen consortium, psoriasis had a suggestive association with vulvar cancer (OR = 1.182, 95%CI: 1.023-1.366, P = 0.024), uterine corpus cancer (OR = 0.937, 95%CI: 0.883-0.993, P = 0.028), and prostate cancer (OR = 0.973, 95%CI: 0.948-0.999, P = 0.045). In an additional large-scale cancer dataset, psoriasis also showed a suggestive association with prostate cancer (OR = 0.968, 95%CI:0.942-0.995, P = 0.020). The meta-analysis confirmed the suggestive association of psoriasis with uterine corpus (OR = 0.931, 95% CI: 0.889-0.976, P = 0.003) and prostate cancer (OR = 0.976, 95% CI: 0.955-0.997, P = 0.023). Whereas the effect of psoriasis on colon and vulvar cancer was not in the same direction across different populations. Furthermore, no association between genetically predicted psoriasis and other cancers were observed.
conclusionsThis comprehensive MR study suggests that psoriasis may be a potential protective factor for uterine corpus cancer in women and prostate cancer in men.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.